Dermatology Therapeutics
1. Abreva patent expiration
Treatment: Treats cold sores/fever blisters on the face or lips. shortens healing time and duration of symptoms: tingling, pain, burning and/or itching
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5534554 | HALEON US HOLDINGS | Sucrose ester-C20 to C28 alcohol formulations |
Dec, 2013
(12 years ago) | |
| US4874794 | HALEON US HOLDINGS | Inflammatory disease treatment |
Apr, 2014
(11 years ago) | |
Drugs and Companies using DOCOSANOL ingredient
Market Authorisation Date: 25 July, 2000
Dosage: CREAM
More Information on Dosage
ABREVA family patents
2. Aklief patent expiration
Treatment: Method of activating rargamma receptor; Treatment of acne vulgaris; Topical treatment of acne vulgaris
AKLIEF's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7807708 | GALDERMA LABS LP | Ligands that modulate RAR receptors and pharmaceutical/cosmetic compositions comprised thereof |
Jul, 2031
(5 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8470871 | GALDERMA LABS LP | Ligands that modulate RAR receptors |
Dec, 2025
(19 days ago) | |
| US9084778 | GALDERMA LABS LP | Topical compositions containing a retinoid of the oil-in-water emulsion type |
May, 2033
(7 years from now) | |
| US8227507 | GALDERMA LABS LP | Ligands that modulate RAR receptors |
Dec, 2025
(19 days ago) | |
| US9498465 | GALDERMA LABS LP | Topical compositions in the form of a gel containing a particular solubilized retinoid |
May, 2033
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 04, 2024 |
Drugs and Companies using TRIFAROTENE ingredient
NCE-1 date: 05 October, 2023
Market Authorisation Date: 04 October, 2019
Dosage: CREAM
More Information on Dosage
AKLIEF family patents
3. Altabax patent
expiration
Treatment: Treatment of impetigo due to staphylococcus aureus or streptococcus pyogenes
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7875630 | ALMIRALL | Process salts compositions and use |
Feb, 2027
(1 year, 1 month from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| USRE43390 | ALMIRALL | Pleuromutilin derivatives as antimicrobials |
Apr, 2021
(4 years ago) | |
| USRE39128 | ALMIRALL | Pleuromutilin derivatives as antimicrobials |
Apr, 2021
(4 years ago) | |
| US8207191 | ALMIRALL | Process, salts, composition and use |
Aug, 2024
(1 year, 4 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 12, 2012 |
Drugs and Companies using RETAPAMULIN ingredient
NCE-1 date: 13 April, 2011
Market Authorisation Date: 12 April, 2007
Dosage: OINTMENT
More Information on Dosage
ALTABAX family patents
4. Anzupgo patent expiration
Treatment: Method of inhibiting janus kinase 2 or janus kinase 3 to treat moderate to severe chronic hand eczema (che) in adults who have had an inadequate response to, or for whom topical corticosteroids are no...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8609647 | LEO PHARMA AS | NA |
Sep, 2031
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 23, 2030 |
Drugs and Companies using DELGOCITINIB ingredient
NCE-1 date: 23 July, 2029
Market Authorisation Date: 23 July, 2025
Dosage: CREAM
More Information on Dosage
ANZUPGO family patents
5. Cibinqo patent expiration
Treatment: Treatment of adults with refractory, moderate-to-severe atopic dermatitis not adequately controlled with other systemic drug products or when use of those therapies is inadvisable
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9035074 | PFIZER | Pyrrolo[2,3-D]pyrimidine derivatives |
Feb, 2034
(8 years from now) | |
| US9545405 | PFIZER | Pyrrolo[2,3-D]pyrimidine derivatives |
Feb, 2034
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9549929 | PFIZER | Pyrrolo[2,3-D]pyrimidine derivatives |
Feb, 2034
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Feb 09, 2026 |
| New Chemical Entity Exclusivity(NCE) | Jan 14, 2027 |
Drugs and Companies using ABROCITINIB ingredient
NCE-1 date: 14 January, 2026
Market Authorisation Date: 14 January, 2022
Dosage: TABLET
More Information on Dosage
CIBINQO family patents
6. Clarinex patent expiration
Treatment: Treatment of chronic idiopathic urticaria; A method of treating nasal and non-nasal symptoms of seasonal allergic rhinitis; Treatment of allergic rhinitis; Administering desloratadine to treat the sym...
CLARINEX IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US6100274 (Pediatric) | ORGANON | 8-chloro-6,11-dihydro-11- ](4-piperidylidine)-5H-benzo[5,6]cyclohepta[1,2-bpyridine oral compositions |
Jan, 2020
(6 years ago) | |
|
US7214684 (Pediatric) | ORGANON | Methods for the treatment of allergic rhinitis |
Jun, 2015
(10 years ago) | |
|
US5607697 (Pediatric) | ORGANON | Taste masking microparticles for oral dosage forms |
Dec, 2015
(10 years ago) | |
| US7211582 | ORGANON | Methods for treating urticaria using descarboethoxyloratadine |
Dec, 2014
(11 years ago) | |
| US7618649 | ORGANON | Extended release oral dosage composition |
Dec, 2020
(5 years ago) | |
| US7214684 | ORGANON | Methods for the treatment of allergic rhinitis |
Dec, 2014
(11 years ago) | |
| US7214683 | ORGANON | Compositions of descarboethoxyloratadine |
Dec, 2014
(11 years ago) | |
| US5607697 | ORGANON | Taste masking microparticles for oral dosage forms |
Jun, 2015
(10 years ago) | |
| US6100274 | ORGANON | 8-chloro-6,11-dihydro-11- ](4-piperidylidine)-5H-benzo[5,6]cyclohepta[1,2-bpyridine oral compositions |
Jul, 2019
(6 years ago) | |
|
US7214683 (Pediatric) | ORGANON | Compositions of descarboethoxyloratadine |
Jun, 2015
(10 years ago) | |
|
US7211582 (Pediatric) | ORGANON | Methods for treating urticaria using descarboethoxyloratadine |
Jun, 2015
(10 years ago) | |
|
US7618649 (Pediatric) | ORGANON | Extended release oral dosage composition |
Jun, 2021
(4 years ago) | |
|
US7405223 (Pediatric) | ORGANON | Treating allergic and inflammatory conditions |
Jan, 2020
(6 years ago) | |
| US7405223 | ORGANON | Treating allergic and inflammatory conditions |
Jul, 2019
(6 years ago) | |
Drugs and Companies using DESLORATADINE ingredient
Market Authorisation Date: 14 July, 2005
Dosage: TABLET, ORALLY DISINTEGRATING; TABLET
How can I launch a generic of CLARINEX before it's drug patent expiration?
More Information on Dosage
CLARINEX family patents
7. Clarinex patent expiration
Treatment: Treatment of allergic rhinitis; Treatment of chronic idiopathic urticaria
CLARINEX IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6514520 | MERCK SHARP DOHME | Stabilized antihistamine syrup |
Jun, 2018
(7 years ago) | |
| US7214684 | MERCK SHARP DOHME | Methods for the treatment of allergic rhinitis |
Dec, 2014
(11 years ago) | |
| US7214683 | MERCK SHARP DOHME | Compositions of descarboethoxyloratadine |
Dec, 2014
(11 years ago) | |
| US7211582 | MERCK SHARP DOHME | Methods for treating urticaria using descarboethoxyloratadine |
Dec, 2014
(11 years ago) | |
|
US7214684 (Pediatric) | MERCK SHARP DOHME | Methods for the treatment of allergic rhinitis |
Jun, 2015
(10 years ago) | |
|
US7214683 (Pediatric) | MERCK SHARP DOHME | Compositions of descarboethoxyloratadine |
Jun, 2015
(10 years ago) | |
|
US7211582 (Pediatric) | MERCK SHARP DOHME | Methods for treating urticaria using descarboethoxyloratadine |
Jun, 2015
(10 years ago) | |
|
US6514520 (Pediatric) | MERCK SHARP DOHME | Stabilized antihistamine syrup |
Dec, 2018
(7 years ago) | |
Drugs and Companies using DESLORATADINE ingredient
Market Authorisation Date: 01 September, 2004
Dosage: SOLUTION
How can I launch a generic of CLARINEX before it's drug patent expiration?
More Information on Dosage
CLARINEX family patents
8. Elidel patent expiration
Treatment: NA
ELIDEL IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US5912238 (Pediatric) | BAUSCH | Heteroatoms-containing tricyclic compounds |
Dec, 2016
(9 years ago) | |
|
US6352998 (Pediatric) | BAUSCH | Pharmaceutical compositions |
Apr, 2016
(9 years ago) | |
| US5912238 | BAUSCH | Heteroatoms-containing tricyclic compounds |
Jun, 2016
(9 years ago) | |
| US6352998 | BAUSCH | Pharmaceutical compositions |
Oct, 2015
(10 years ago) | |
|
US6423722 (Pediatric) | BAUSCH | Crystalline macrolides and process for their preparation |
Dec, 2018
(7 years ago) | |
| US6423722 | BAUSCH | Crystalline macrolides and process for their preparation |
Jun, 2018
(7 years ago) | |
Drugs and Companies using PIMECROLIMUS ingredient
Market Authorisation Date: 13 December, 2001
Dosage: CREAM
More Information on Dosage
ELIDEL family patents
9. Ertaczo patent expiration
Treatment: Product is approved for the topical treatment of tinea pedis
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5135943 | LACER PHARMA | 1H-imidazole derivative compounds and pharmaceutical compositions containing the same |
May, 2014
(11 years ago) | |
Drugs and Companies using SERTACONAZOLE NITRATE ingredient
Market Authorisation Date: 10 December, 2003
Dosage: CREAM
More Information on Dosage
ERTACZO family patents
10. Eucrisa patent expiration
Treatment: Method of treating mild to moderate atopic dermatitis.
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8039451 | ANACOR PHARMS INC | Boron-containing small molecules |
Jun, 2029
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8501712 | ANACOR PHARMS INC | Boron-containing small molecules as anti-inflammatory agents |
Feb, 2027
(1 year, 1 month from now) | |
| US9682092 | ANACOR PHARMS INC | Boron-containing small molecules as anti-inflammatory agents |
Feb, 2027
(1 year, 1 month from now) | |
| US8168614 | ANACOR PHARMS INC | Boron-containing small molecules as anti-inflammatory agents |
Jan, 2030
(4 years from now) | |
|
US8039451 (Pediatric) | ANACOR PHARMS INC | Boron-containing small molecules |
Dec, 2029
(3 years from now) | |
|
US8168614 (Pediatric) | ANACOR PHARMS INC | Boron-containing small molecules as anti-inflammatory agents |
Jul, 2030
(4 years from now) | |
|
US8501712 (Pediatric) | ANACOR PHARMS INC | Boron-containing small molecules as anti-inflammatory agents |
Aug, 2027
(1 year, 7 months from now) | |
|
US9682092 (Pediatric) | ANACOR PHARMS INC | Boron-containing small molecules as anti-inflammatory agents |
Aug, 2027
(1 year, 7 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 14, 2021 |
| New Patient Population(NPP) | Mar 23, 2023 |
| Pediatric Exclusivity(PED) | Sep 23, 2023 |
| New Dosing Schedule(D-191) | Apr 03, 2026 |
Drugs and Companies using CRISABOROLE ingredient
NCE-1 date: 23 September, 2022
Market Authorisation Date: 14 December, 2016
Dosage: OINTMENT
How can I launch a generic of EUCRISA before it's drug patent expiration?
More Information on Dosage
EUCRISA family patents
11. Filsuvez patent expiration
Treatment: Use of birch triterpenes for the treatment of wounds associated with dystrophic and junctional epidermolysis bullosa
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11266660 | CHIESI | Betulin-containing birch bark extracts and their formulation |
Jan, 2039
(12 years from now) | |
| US9827214 | CHIESI | Use of an oleogel containing triterpene for healing wounds |
Nov, 2030
(4 years from now) | |
| US9352041 | CHIESI | Use of an oleogel containing triterpene for healing wounds |
Nov, 2030
(4 years from now) | |
| US12268695 | CHIESI | Betulin-containing birch bark extracts and their formulation |
Jan, 2039
(12 years from now) | |
| US11083733 | CHIESI | Betulin-containing birch bark extracts and their formulation |
Jan, 2039
(12 years from now) | |
| US8828444 | CHIESI | Triterpene-containing oleogel-forming agent, triterpene-containing oleogel and method for producing a triterpene-containing oleogel |
Jun, 2026
(5 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 18, 2028 |
| Orphan Drug Exclusivity(ODE-460) | Dec 18, 2030 |
Drugs and Companies using BIRCH TRITERPENES ingredient
NCE-1 date: 19 December, 2027
Market Authorisation Date: 18 December, 2023
Dosage: GEL
More Information on Dosage
FILSUVEZ family patents
12. Jublia patent expiration
Treatment: Antimycotic uses, specifically treatment of onychomycosis; Topical treatment of onychomycosis of the toenail(s) due to trichophyton rubrum and trichophyton mentagrophytes; Topical treatment of the toe...
JUBLIA IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7214506 | BAUSCH | Method for treating onychomycosis |
Feb, 2026
(a month from now) | |
| US9566272 | BAUSCH | Compositions and methods for treating diseases of the nail |
Jan, 2028
(1 year, 11 months from now) | |
| US9877955 | BAUSCH | Compositions and methods for treating diseases of the nail |
Jan, 2028
(1 year, 11 months from now) | |
| US10512640 | BAUSCH | Compositions and methods for treating diseases of the nail |
Jan, 2028
(1 year, 11 months from now) | |
| US10342875 | BAUSCH | Stabilized efinaconazole compositions |
Oct, 2034
(8 years from now) | |
| US11213519 | BAUSCH | Compositions and methods for treating diseases of the nail |
Jan, 2028
(1 year, 11 months from now) | |
| US10478601 | BAUSCH | Applicator |
Apr, 2035
(9 years from now) | |
| US11654139 | BAUSCH | Anti-infective methods, compositions, and devices |
Oct, 2034
(8 years from now) | |
| US10828293 | BAUSCH | Anti-infective methods, compositions, and devices |
Oct, 2034
(8 years from now) | |
| US10864274 | BAUSCH | Stabilized efinaconazole formulations |
Oct, 2034
(8 years from now) | |
| US11872218 | BAUSCH | Compositions and methods for treating diseases of the nail |
Jan, 2028
(1 year, 11 months from now) | |
| US8039494 | BAUSCH | Compositions and methods for treating diseases of the nail |
Jul, 2030
(4 years from now) | |
| US9662394 | BAUSCH | Stabilized efinaconazole compositions |
Oct, 2034
(8 years from now) | |
| US9861698 | BAUSCH | Compositions and methods for treating diseases of the nail |
Jul, 2030
(4 years from now) | |
| US8486978 | BAUSCH | Compositions and methods for treating diseases of the nail |
Oct, 2030
(4 years from now) | |
| US10105444 | BAUSCH | Compositions and methods for treating diseases of the nail |
Jul, 2030
(4 years from now) | |
| US9302009 | BAUSCH | Compositions and methods for treating diseases of the nail |
Oct, 2030
(4 years from now) | |
| US10828369 | BAUSCH | Compositions and methods for treating diseases of the nail |
Jan, 2028
(1 year, 11 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 06, 2019 |
| New Patient Population(NPP) | Apr 27, 2023 |
Drugs and Companies using EFINACONAZOLE ingredient
NCE-1 date: 06 June, 2018
Market Authorisation Date: 06 June, 2014
Dosage: SOLUTION
How can I launch a generic of JUBLIA before it's drug patent expiration?
More Information on Dosage
JUBLIA family patents
13. Kerydin patent expiration
Treatment: Treatment for onychomycosis that is tinea unguium; Treatment of onychomychosis of a toenail caused by trichophyton rubrum or trichophyton mentagrophytes; Treatment of onychomycosis of a toenail
KERYDIN IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9566289 | ANACOR PHARMS INC | Boron-containing small molecules |
Feb, 2026
(a month from now) | |
| US7582621 | ANACOR PHARMS INC | Boron-containing small molecules |
May, 2027
(1 year, 4 months from now) | |
| US9566290 | ANACOR PHARMS INC | Boron-containing small molecules |
Feb, 2026
(a month from now) | |
|
US9566290 (Pediatric) | ANACOR PHARMS INC | Boron-containing small molecules |
Aug, 2026
(7 months from now) | |
|
US9572823 (Pediatric) | ANACOR PHARMS INC | Boron-containing small molecules |
Aug, 2026
(7 months from now) | |
|
US9549938 (Pediatric) | ANACOR PHARMS INC | Boron-containing small molecules |
Aug, 2026
(7 months from now) | |
| US9549938 | ANACOR PHARMS INC | Boron-containing small molecules |
Feb, 2026
(a month from now) | |
| US7767657 | ANACOR PHARMS INC | Boron-containing small molecules |
May, 2027
(1 year, 4 months from now) | |
| US9572823 | ANACOR PHARMS INC | Boron-containing small molecules |
Feb, 2026
(a month from now) | |
|
US9566289 (Pediatric) | ANACOR PHARMS INC | Boron-containing small molecules |
Aug, 2026
(7 months from now) | |
|
US7582621 (Pediatric) | ANACOR PHARMS INC | Boron-containing small molecules |
Nov, 2027
(1 year, 10 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 07, 2019 |
| Pediatric Exclusivity(PED) | Jan 07, 2020 |
Drugs and Companies using TAVABOROLE ingredient
NCE-1 date: 07 January, 2019
Market Authorisation Date: 07 July, 2014
Dosage: SOLUTION
How can I launch a generic of KERYDIN before it's drug patent expiration?
More Information on Dosage
KERYDIN family patents
14. Klisyri patent expiration
Treatment: Topical treatment of actinic keratosis of the face or scalp
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7851470 | ALMIRALL | Composition and methods for modulating a kinase cascade |
Feb, 2029
(3 years from now) | |
| US8236799 | ALMIRALL | Biaryl compositions and methods for modulating a kinase cascade |
Dec, 2025
(12 days ago) | |
| US8980890 | ALMIRALL | Compositions and methods of treating cell proliferation disorders |
Dec, 2025
(12 days ago) | |
| US7300931 | ALMIRALL | Compositions for treating cell proliferation disorders |
Dec, 2030
(4 years from now) | |
| US10669236 | ALMIRALL | Solid forms of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide |
Sep, 2038
(12 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10617693 | ALMIRALL | Methods of treating and/or preventing actinic keratosis |
Mar, 2038
(12 years from now) | |
| US11497750 | ALMIRALL | Methods of treating and/or preventing actinic keratosis |
Mar, 2038
(12 years from now) | |
| US10323001 | ALMIRALL | Compositions for modulating a kinase cascade and methods of use thereof |
Dec, 2027
(1 year, 11 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 14, 2025 |
| New Dosing Schedule(D-192) | Jun 07, 2027 |
Drugs and Companies using TIRBANIBULIN ingredient
NCE-1 date: 14 December, 2024
Market Authorisation Date: 14 December, 2020
Dosage: OINTMENT
More Information on Dosage
KLISYRI family patents
15. Kybella patent expiration
Treatment: Method for reduction of submental fat; Improvement in the appearance of moderate to severe convexity or fullness associated with submental fat in adults by means of reducing submental fat volume as de...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8242294 | ABBVIE | Synthetic bile acid compositions and methods |
May, 2028
(2 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7622130 | ABBVIE | Methods and compositions for the non-surgical removal of fat |
Dec, 2027
(1 year, 10 months from now) | |
| US7754230 | ABBVIE | Methods and related compositions for reduction of fat |
Dec, 2027
(1 year, 10 months from now) | |
| US8846066 | ABBVIE | Methods and related compositions for reduction of fat and skin tightening |
Feb, 2025
(10 months ago) | |
| US12161653 | ABBVIE | Treatment of submental fat |
Feb, 2032
(6 years from now) | |
| US8298556 | ABBVIE | Methods and related compositions for the non-surgical removal of fat |
Aug, 2025
(5 months ago) | |
| US9949986 | ABBVIE | Synthetic bile acid compositions and methods |
Feb, 2028
(2 years from now) | |
| US9636349 | ABBVIE | Synthetic bile acid compositions and methods |
Feb, 2028
(2 years from now) | |
| US9522155 | ABBVIE | Synthetic bile acid compositions and methods |
Feb, 2028
(2 years from now) | |
| US8546367 | ABBVIE | Synthetic bile acid compositions and methods |
Feb, 2028
(2 years from now) | |
| US8461140 | ABBVIE | Synthetic bile acid compositions and methods |
Feb, 2028
(2 years from now) | |
| US8653058 | ABBVIE | Compositions comprising deoxycholic acid and salts thereof suitable for use in treating fat deposits |
Mar, 2030
(4 years from now) | |
| US8367649 | ABBVIE | Formulations of deoxycholic acid and salts thereof |
Mar, 2030
(4 years from now) | |
| US8101593 | ABBVIE | Formulations of deoxycholic acid and salts thereof |
Mar, 2030
(4 years from now) | |
| US10500214 | ABBVIE | Formulations of deoxycholic acid and salts thereof |
Mar, 2030
(4 years from now) | |
| US8883770 | ABBVIE | Synthetic bile acid compositions and methods |
Feb, 2028
(2 years from now) | |
Drugs and Companies using DEOXYCHOLIC ACID ingredient
Market Authorisation Date: 29 April, 2015
Dosage: SOLUTION
How can I launch a generic of KYBELLA before it's drug patent expiration?
More Information on Dosage
KYBELLA family patents
16. Leqselvi patent expiration
Treatment: Treatment of adult patients with alopecia areata
LEQSELVI IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US12247034 | SUN PHARM INDS INC | Crystalline form of deuruxolitinib phosphate |
May, 2044
(18 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12285432 | SUN PHARM INDS INC | Treatment of hair loss disorders with deuterated JAK inhibitors |
Aug, 2042
(16 years from now) | |
| US12364699 | SUN PHARM INDS INC | NA |
Oct, 2044
(18 years from now) | |
| US11919907 | SUN PHARM INDS INC | Deuterated JAK inhibitor and uses thereof |
May, 2041
(15 years from now) | |
| US10561659 | SUN PHARM INDS INC | Treatment of hair loss disorders with deuterated JAK inhibitors |
May, 2037
(11 years from now) | |
| US12076323 | SUN PHARM INDS INC | Treatment of hair loss disorders with deuterated JAK inhibitors |
May, 2037
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 25, 2029 |
Drugs and Companies using DEURUXOLITINIB PHOSPHATE ingredient
NCE-1 date: 25 July, 2028
Market Authorisation Date: 25 July, 2024
Dosage: TABLET
More Information on Dosage
LEQSELVI family patents
17. Litfulo patent expiration
Treatment: Method of treating severe alopecia areata in adults and adolescents 12 years and older by administering ritlectinib
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US12116368 | PFIZER | Pyrrolo[2,3-d]pyrimidine tosylate salt, crystalline form thereof and manufacturing process and intermediates thereto |
Oct, 2041
(15 years from now) | |
| US9617258 | PFIZER | Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides |
Dec, 2034
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12077533 | PFIZER | Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides |
Dec, 2034
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 23, 2028 |
Drugs and Companies using RITLECITINIB TOSYLATE ingredient
NCE-1 date: 24 June, 2027
Market Authorisation Date: 23 June, 2023
Dosage: CAPSULE
More Information on Dosage
LITFULO family patents
18. Lumigan patent expiration
Treatment: Lumigan is a prostaglandin analog indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; A method of lowering intraocular pressure; A...
LUMIGAN's oppositions filed in EPO
LUMIGAN IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7851504 | ABBVIE | Enhanced bimatoprost ophthalmic solution |
Jun, 2027
(1 year, 5 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5688819 | ABBVIE | Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents |
Aug, 2014
(11 years ago) | |
| US6403649 | ABBVIE | Non-acidic cyclopentane heptanoic acid,2-cycloalkyl or arylalkyl derivatives as therapeutic agents |
Sep, 2012
(13 years ago) | |
| US8017655 | ABBVIE | Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents |
Nov, 2012
(13 years ago) | |
| US9155716 | ABBVIE | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(9 months ago) | |
| US8299118 | ABBVIE | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(9 months ago) | |
| US9241918 | ABBVIE | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(9 months ago) | |
| US8309605 | ABBVIE | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(9 months ago) | |
| US8338479 | ABBVIE | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(9 months ago) | |
| US8524777 | ABBVIE | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(9 months ago) | |
| US8586630 | ABBVIE | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(9 months ago) | |
| US8278353 | ABBVIE | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(9 months ago) | |
| US8933127 | ABBVIE | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(9 months ago) | |
| US8933120 | ABBVIE | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(9 months ago) | |
| US8772338 | ABBVIE | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(9 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Aug 31, 2013 |
Drugs and Companies using BIMATOPROST ingredient
Market Authorisation Date: 16 March, 2001
Dosage: SOLUTION/DROPS
How can I launch a generic of LUMIGAN before it's drug patent expiration?
More Information on Dosage
LUMIGAN family patents
19. Luzu patent expiration
Treatment: Treatment of fungal infections
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9012484 | BAUSCH | Crystal and pharmaceutical preparation containing the same crystal |
Sep, 2033
(7 years from now) | |
| US5900488 | BAUSCH | Method for treating mycosis using imidazolylacetonitrile derivatives |
Jan, 2020
(5 years ago) | |
| US9453006 | BAUSCH | Crystalline form having specific crystal habit and pharmaceutical composition containing this crystalline form as active ingredient |
Sep, 2033
(7 years from now) | |
| US9199977 | BAUSCH | Crystal having crystal habits and pharmaceutical composition obtained by processing the crystal |
Sep, 2033
(7 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8980931 | BAUSCH | Method of evaluating pharmaceutical preparation containing luliconazole and index substance |
Apr, 2034
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 14, 2018 |
| New Patient Population(NPP) | Feb 20, 2021 |
Drugs and Companies using LULICONAZOLE ingredient
NCE-1 date: 14 November, 2017
Market Authorisation Date: 14 November, 2013
Dosage: CREAM
More Information on Dosage
LUZU family patents
20. Natroba patent expiration
Treatment: Topical treatment of head lice infestation in patients four (4) years of age and older; The product composition (natroba) is for the topical treatment of human scabies mite infestations by melting and...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7030095 | CIPHER | Pediculicidal and ovacidal treatment compositions and methods for killing head lice and their eggs |
Jul, 2021
(4 years ago) | |
| US6063771 | CIPHER | Formulations for controlling human lice |
Jun, 2019
(6 years ago) | |
| US5496931 | CIPHER | Insecticide and miticide A83543 compounds and their method of production by fermentation |
Mar, 2013
(12 years ago) | |
| US6342482 | CIPHER | Formulations for controlling human lice |
Jun, 2019
(6 years ago) | |
| US9895388 | CIPHER | Methods and compositions useful for controlling cutaneous mites |
Nov, 2033
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 18, 2016 |
| M(M-152) | Nov 30, 2017 |
| New Indication(I-858) | Apr 28, 2024 |
Drugs and Companies using SPINOSAD ingredient
NCE-1 date: 18 January, 2015
Market Authorisation Date: 18 January, 2011
Dosage: SUSPENSION
More Information on Dosage
NATROBA family patents
21. Otezla patent expiration
Treatment: Treatment of patients with plaque psoriasis who are candidates for phototherapy or systemic therapy; Use of otezla (apremilast) for the treatment of psoriatic arthritis; Treatment of adult patients wi...
OTEZLA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6020358 | AMGEN INC | Substituted phenethylsulfones and method of reducing TNFα levels |
Oct, 2018
(7 years ago) | |
| US7893101 | AMGEN INC | Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof |
Dec, 2023
(2 years ago) | |
| US7427638 | AMGEN INC | (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione:, and methods of synthesis and compositions thereof |
Feb, 2028
(2 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8455536 | AMGEN INC | Methods of using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline 1,3-dione |
Mar, 2023
(2 years ago) | |
| US8802717 | AMGEN INC | Methods of treating arthritic conditions using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline 1,3-dione |
Mar, 2023
(2 years ago) | |
| US7208516 | AMGEN INC | Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione |
Mar, 2023
(2 years ago) | |
| US7659302 | AMGEN INC | Methods of using (+)-2-[1-(3-ethoxy-4 methoxyphenyl)-2-methylsulfonylethyl]-4 acetylaminoisoindoline 1,3-dione |
Mar, 2023
(2 years ago) | |
| US9018243 | AMGEN INC | Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof |
Mar, 2023
(2 years ago) | |
| US6962940 | AMGEN INC | (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof |
Mar, 2023
(2 years ago) | |
| US9724330 | AMGEN INC | Methods of using (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione |
Mar, 2023
(2 years ago) | |
| US10092541 | AMGEN INC | Methods for the treatment of diseases ameliorated by PDE4 inhibition using dosage titration of apremilast |
May, 2034
(8 years from now) | |
| US9872854 | AMGEN INC | Methods for the treatment of psoriatic arthritis using apremilast |
May, 2034
(8 years from now) | |
|
US7427638 (Pediatric) | AMGEN INC | (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione:, and methods of synthesis and compositions thereof |
Aug, 2028
(2 years from now) | |
|
US9872854 (Pediatric) | AMGEN INC | Methods for the treatment of psoriatic arthritis using apremilast |
Nov, 2034
(8 years from now) | |
|
US10092541 (Pediatric) | AMGEN INC | Methods for the treatment of diseases ameliorated by PDE4 inhibition using dosage titration of apremilast |
Nov, 2034
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-694) | Sep 23, 2017 |
| New Chemical Entity Exclusivity(NCE) | Mar 21, 2019 |
| New Indication(I-803) | Jul 19, 2022 |
| M(M-257) | Apr 10, 2023 |
| New Indication(I-884) | Dec 20, 2024 |
| Orphan Drug Exclusivity(ODE-248) | Jul 19, 2026 |
| M(M-299) | Jul 20, 2026 |
| Pediatric Exclusivity(PED) | Jan 20, 2027 |
| New Patient Population(NPP) | Apr 25, 2027 |
Drugs and Companies using APREMILAST ingredient
NCE-1 date: 20 January, 2026
Market Authorisation Date: 21 March, 2014
Dosage: TABLET
How can I launch a generic of OTEZLA before it's drug patent expiration?
More Information on Dosage
OTEZLA family patents
22. Panretin patent expiration
Treatment: Topical treatment of cutaneous lesions in patients with aids-related kaposi's sarcoma
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5932622 | ADVANZ PHARMA | Method for in vivo modulation of non-malignant skin-related processes with 9-cis-retinoic acid |
Aug, 2016
(9 years ago) | |
Drugs and Companies using ALITRETINOIN ingredient
Market Authorisation Date: 02 February, 1999
Dosage: GEL
More Information on Dosage
PANRETIN family patents
23. Picato patent expiration
Treatment: Treatment of actinic keratosis; Use of ingenol mebutate to treat actinic keratosis; To stimulate the immune system to induce t cell proliferation; To inhibit the proliferative activity of neoplastic c...
PICATO's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6787161 | LEO LABS | Anti-cancer compounds |
Aug, 2018
(7 years ago) | |
| US8536163 | LEO LABS | Therapeutic compositions |
Dec, 2026
(11 months from now) | |
| US6432452 | LEO LABS | Anti-cancer compounds |
Aug, 2018
(7 years ago) | |
| US6844013 | LEO LABS | Methods of stimulating the immune system |
Dec, 2018
(7 years ago) | |
| US7410656 | LEO LABS | Anti-cancer compounds |
Aug, 2018
(7 years ago) | |
| US8716271 | LEO LABS | Therapeutic compositions |
Dec, 2026
(11 months from now) | |
| US9861603 | LEO LABS | Therapeutic compositions |
Dec, 2026
(11 months from now) | |
| US8735375 | LEO LABS | Therapeutic compositions |
Dec, 2026
(11 months from now) | |
| US9820959 | LEO LABS | Therapeutic compositions |
Dec, 2026
(11 months from now) | |
| US9789078 | LEO LABS | Method of topically treating actinic keratosis with ingenol mebutate cycle therapy |
May, 2033
(7 years from now) | |
| US9833429 | LEO LABS | Therapeutic compositions |
Dec, 2026
(11 months from now) | |
| US8377919 | LEO LABS | Therapeutic compositions |
Dec, 2026
(11 months from now) | |
| US8372827 | LEO LABS | Therapeutic compositions |
Dec, 2026
(11 months from now) | |
| US8372828 | LEO LABS | Therapeutic compositions |
Dec, 2026
(11 months from now) | |
| US9833428 | LEO LABS | Therapeutic compositions |
Dec, 2026
(11 months from now) | |
| US8278292 | LEO LABS | Therapeutic compositions |
Jul, 2027
(1 year, 5 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 23, 2017 |
| M(M-169) | Nov 19, 2018 |
Drugs and Companies using INGENOL MEBUTATE ingredient
NCE-1 date: 24 January, 2016
Market Authorisation Date: 23 January, 2012
Dosage: GEL
How can I launch a generic of PICATO before it's drug patent expiration?
More Information on Dosage
PICATO family patents
24. Rhapsido patent expiration
Treatment: Treatment of chronic autoimmune urticaria; Treatment of chronic spontaneous urticaria
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9512084 | NOVARTIS | NA |
Nov, 2034
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10457647 | NOVARTIS | NA |
Nov, 2034
(8 years from now) | |
| US12419889 | NOVARTIS | NA |
Jan, 2043
(17 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 30, 2030 |
Drugs and Companies using REMIBRUTINIB ingredient
NCE-1 date: 30 September, 2029
Market Authorisation Date: 30 September, 2025
Dosage: TABLET
More Information on Dosage
RHAPSIDO family patents
25. Sofdra patent expiration
Treatment: Topical treatment of primary axillary hyperhidrosis in adults and pediatric patients 9 years of age and older
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8147809 | BOTANIX SB | Soft anticholinergic esters |
Mar, 2027
(1 year, 2 months from now) | |
| US11566000 | BOTANIX SB | Crystalline form of sofpironium bromide and preparation method thereof |
May, 2040
(14 years from now) | |
| US11584715 | BOTANIX SB | Crystalline form of sofpironium bromide and preparation method thereof |
May, 2040
(14 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12357609 | BOTANIX SB | NA |
May, 2034
(8 years from now) | |
| US12398102 | BOTANIX SB | NA |
May, 2034
(8 years from now) | |
| US12156865 | BOTANIX SB | Formulation for soft anticholinergic analogs |
May, 2034
(8 years from now) | |
| US11123325 | BOTANIX SB | Formulation for soft anticholinergic analogs |
Jul, 2037
(11 years from now) | |
| US11084788 | BOTANIX SB | Formulation for soft anticholinergic analogs |
May, 2034
(8 years from now) | |
| US11052067 | BOTANIX SB | Formulation for soft anticholinergic analogs |
May, 2034
(8 years from now) | |
| US11034652 | BOTANIX SB | Formulation for soft anticholinergic analogs |
May, 2034
(8 years from now) | |
| US11026919 | BOTANIX SB | Formulation for soft anticholinergic analogs |
May, 2034
(8 years from now) | |
| US10961191 | BOTANIX SB | Formulation for soft anticholinergic analogs |
May, 2034
(8 years from now) | |
| US10959983 | BOTANIX SB | Formulation for soft anticholinergic analogs |
May, 2034
(8 years from now) | |
| US9220707 | BOTANIX SB | Method of dosing and use of soft anticholinergic esters |
Mar, 2034
(8 years from now) | |
| US8628759 | BOTANIX SB | Soft anticholinergic esters |
Nov, 2026
(10 months from now) | |
| US10952990 | BOTANIX SB | Formulation for soft anticholinergic analogs |
May, 2034
(8 years from now) | |
| US10947192 | BOTANIX SB | Formulation for soft anticholinergic analogs |
May, 2034
(8 years from now) | |
| US10383846 | BOTANIX SB | Method of dosing and use of soft anticholinergic esters |
Mar, 2034
(8 years from now) | |
| US9492429 | BOTANIX SB | Method of dosing and use of soft anticholinergic esters |
Mar, 2034
(8 years from now) | |
| US9895350 | BOTANIX SB | Method of dosing and use of soft anticholinergic esters |
Mar, 2034
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 20, 2029 |
Drugs and Companies using SOFPIRONIUM BROMIDE ingredient
NCE-1 date: 20 June, 2028
Market Authorisation Date: 18 June, 2024
Dosage: GEL, METERED
More Information on Dosage
SOFDRA family patents
26. Sotyktu patent expiration
Treatment: Treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE47929 | BRISTOL | Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFNα responses |
Nov, 2033
(7 years from now) | |
| US10000480 | BRISTOL | Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses |
Nov, 2033
(7 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11021475 | BRISTOL | Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses |
Nov, 2033
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 09, 2027 |
Drugs and Companies using DEUCRAVACITINIB ingredient
NCE-1 date: 09 September, 2026
Market Authorisation Date: 09 September, 2022
Dosage: TABLET
More Information on Dosage
SOTYKTU family patents
27. Ulesfia patent expiration
Treatment: Topical treatment of lice infestations
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5858383 | SHIONOGI INC | Methods and compositions for topical treatment of ectoparasites |
Aug, 2017
(8 years ago) | |
| US6139859 | SHIONOGI INC | Methods and compositions for topical treatment of ectoparasites |
Aug, 2017
(8 years ago) | |
| US6793931 | SHIONOGI INC | Ectoparasite asphyxiator compositions and methods for their applications |
Jul, 2022
(3 years ago) | |
| US7294342 | SHIONOGI INC | Ectoparasite asphyxiator compositions and methods for their application |
May, 2024
(1 year, 7 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 09, 2014 |
Drugs and Companies using BENZYL ALCOHOL ingredient
NCE-1 date: 09 April, 2013
Market Authorisation Date: 09 April, 2009
Dosage: LOTION
How can I launch a generic of ULESFIA before it's drug patent expiration?
More Information on Dosage
ULESFIA family patents
28. Veregen patent expiration
Treatment: Treatment of genital warts
VEREGEN IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10434059 | ANI PHARMS | Medicament for the treatment of viral skin and tumour diseases |
Nov, 2022
(3 years ago) | |
| US5795911 | ANI PHARMS | Composition for treating Condyloma acuminata |
Oct, 2020
(5 years ago) | |
| US5968973 | ANI PHARMS | Method for treating hyperplasia |
Apr, 2017
(8 years ago) | |
| US9770406 | ANI PHARMS | Medicament for the treatment of viral skin and tumour diseases |
Jul, 2025
(5 months ago) | |
| US7858662 | ANI PHARMS | Medicament for the treatment of viral skin and tumour diseases |
Oct, 2026
(8 months from now) | |
Drugs and Companies using SINECATECHINS ingredient
Market Authorisation Date: 31 October, 2006
Dosage: OINTMENT
More Information on Dosage
VEREGEN family patents
29. Vtama patent expiration
Treatment: Topical treatment of plaque psoriasis in adults; Topical treatment of atopic dermatitis in adults and pediatric patients 2 years of age and older
VTAMA's oppositions filed in EPO
VTAMA IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10647649 | ORGANON LLC | Process for preparing tapinarof |
Nov, 2038
(12 years from now) | |
| US11597692 | ORGANON LLC | Process for preparing tapinarof |
Nov, 2038
(12 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11590088 | ORGANON LLC | Use of Tapinarof for the treatment of chronic plaque psoriasis |
Nov, 2039
(13 years from now) | |
| US11612573 | ORGANON LLC | Topical pharmaceutical compositions |
May, 2036
(10 years from now) | |
| US11497718 | ORGANON LLC | Use of tapinarof for the treatment of atopic dermatitis |
Nov, 2039
(13 years from now) | |
| US11938099 | ORGANON LLC | Use of tapinarof for the treatment of atopic dermatitis |
Nov, 2039
(13 years from now) | |
| US10426743 | ORGANON LLC | Topical pharmaceutical compositions |
May, 2036
(10 years from now) | |
| US11617724 | ORGANON LLC | Topical pharmaceutical compositions |
May, 2036
(10 years from now) | |
| US10195160 | ORGANON LLC | Topical pharmaceutical compositions |
May, 2036
(10 years from now) | |
| US11622945 | ORGANON LLC | Topical pharmaceutical compositions |
May, 2036
(10 years from now) | |
| US11458108 | ORGANON LLC | Topical pharmaceutical compositions |
May, 2036
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 23, 2027 |
| New Indication(I-956) | Dec 12, 2027 |
Drugs and Companies using TAPINAROF ingredient
NCE-1 date: 23 May, 2026
Market Authorisation Date: 23 May, 2022
Dosage: CREAM
More Information on Dosage
VTAMA family patents
30. Wayrilz patent expiration
Treatment: Method for treating adult patients with persistent or chronic immune thrombocytopenia (itp) who have had an insufficient response to a previous treatment, by achieving a platelet count of at least 50,...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9994576 | GENZYME CORP | NA |
Sep, 2033
(7 years from now) | |
| US9266895 | GENZYME CORP | NA |
Sep, 2033
(7 years from now) | |
| US8940744 | GENZYME CORP | NA |
Sep, 2033
(7 years from now) | |
| US11708370 | GENZYME CORP | NA |
Feb, 2041
(15 years from now) | |
| US9580427 | GENZYME CORP | NA |
Mar, 2033
(7 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12178818 | GENZYME CORP | NA |
Oct, 2040
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 29, 2030 |
Drugs and Companies using RILZABRUTINIB ingredient
NCE-1 date: 29 August, 2029
Market Authorisation Date: 29 August, 2025
Dosage: TABLET
More Information on Dosage
WAYRILZ family patents
31. Winlevi patent expiration
Treatment: Method of treating acne vulgaris with topically applied cortexolone 17alpha-propionate; Method of treating acne vulgaris with topically applied cortexolone 17a-propionate
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12337002 | SUN PHARM | NA |
Jul, 2028
(2 years from now) | |
| US11207332 | SUN PHARM | Enzymatic process for obtaining 17 α-monoesters of cortexolone and/or its 9,11-dehydroderivatives |
Nov, 2028
(2 years from now) | |
| US10159682 | SUN PHARM | Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives |
Aug, 2028
(2 years from now) | |
| US8143240 | SUN PHARM | 17α, 21-dihydroxypregnene esters as antiandrogenic agents |
Jan, 2026
(2 days from now) | |
| US9486458 | SUN PHARM | Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives |
Jul, 2028
(2 years from now) | |
| US8865690 | SUN PHARM | 17alfa, 21-dihydroxypregnene esters as antiandrogenic agents |
Dec, 2025
(13 days ago) | |
| US9433628 | SUN PHARM | Enzymatic process for obtaining 17α-monoesters of cortexolone and/or its 9,11-dehydroderivatives |
Feb, 2029
(3 years from now) | |
| US9211295 | SUN PHARM | 17 alpha, 21-dihydroxypregnene esters as antiandrogenic agents |
May, 2025
(7 months ago) | |
| US11938141 | SUN PHARM | Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives |
Jul, 2028
(2 years from now) | |
| US8785427 | SUN PHARM | Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives |
Jul, 2030
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 26, 2025 |
Drugs and Companies using CLASCOTERONE ingredient
NCE-1 date: 26 August, 2024
Market Authorisation Date: 26 August, 2020
Dosage: CREAM
More Information on Dosage
WINLEVI family patents
32. Xeglyze patent expiration
Treatment: Topical treatment of head lice infestation in patients 6 months of age and older
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9839631 | HATCHTECH | Methods and compositions for controlling ectoparasites |
Jul, 2024
(1 year, 5 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8212038 | HATCHTECH | Methods and compositions for controlling ectoparasites |
Jul, 2024
(1 year, 5 months ago) | |
| US10292389 | HATCHTECH | Pediculicidal composition |
Dec, 2034
(8 years from now) | |
| US9357783 | HATCHTECH | Methods and compositions for controlling ectoparasites |
Jul, 2024
(1 year, 5 months ago) | |
| US7812163 | HATCHTECH | Methods and compositions for controlling ectoparasites |
Oct, 2026
(9 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 24, 2025 |
Drugs and Companies using ABAMETAPIR ingredient
NCE-1 date: 24 July, 2024
Market Authorisation Date: 24 July, 2020
Dosage: LOTION
More Information on Dosage
XEGLYZE family patents
33. Xepi patent expiration
Treatment: Treatment of impetigo due to staphylococcus aureus or streptococcus pyogenes
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6335447 | FERRER INTERNACIONAL | Quinolonecarboxylic acid derivatives or salts thereof |
Nov, 2023
(2 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9180200 | FERRER INTERNACIONAL | Pharmaceutical topical compositions |
Jan, 2032
(6 years from now) | |
| US9399014 | FERRER INTERNACIONAL | Pharmaceutical topical compositions |
Dec, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 11, 2022 |
Drugs and Companies using OZENOXACIN ingredient
NCE-1 date: 11 December, 2021
Market Authorisation Date: 11 December, 2017
Dosage: CREAM
More Information on Dosage
XEPI family patents
34. Ycanth patent expiration
Treatment: Topical treatment of molluscum contagiosum in adult and pediatric patients 2 years of age and older; Topical treatment of skin lesions caused by an infection with molluscum contagiosum in adult and pe...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12233042 | VERRICA PHARMS | Treatment of cutaneous disorders |
Aug, 2038
(12 years from now) | |
| US11147790 | VERRICA PHARMS | Treatment of cutaneous disorders |
Aug, 2038
(12 years from now) | |
| US11052064 | VERRICA PHARMS | Compositions, methods and systems for the treatment of cutaneous disorders |
May, 2035
(9 years from now) | |
| US12290651 | VERRICA PHARMS | Devices and methods for the treatment of body surface disorders |
Feb, 2041
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 21, 2028 |
Drugs and Companies using CANTHARIDIN ingredient
NCE-1 date: 22 July, 2027
Market Authorisation Date: 21 July, 2023
Dosage: SOLUTION
More Information on Dosage
YCANTH family patents
35. Zelsuvmi patent expiration
Treatment: Method of administering a nitric oxide releasing active pharmaceutical ingredient to treat and/or prevent viral infection; Method of treating and/or preventing viral infection using a nitric oxide rel...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8956658 | LNHC | Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications |
May, 2026
(4 months from now) | |
| US8282967 | LNHC | Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications |
May, 2026
(4 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11723858 | LNHC | Topical antiviral compositions, delivery systems, and methods of using the same |
Jul, 2035
(9 years from now) | |
| US11040006 | LNHC | Topical antiviral compositions, delivery systems, and methods of using the same |
Jul, 2035
(9 years from now) | |
| US10736839 | LNHC | Topical antiviral compositions, delivery systems, and methods of using the same |
Jul, 2035
(9 years from now) | |
| US10322081 | LNHC | Topical antiviral compositions and methods of using the same |
Jul, 2035
(9 years from now) | |
| US10258564 | LNHC | Topical compositions and methods of using the same |
Nov, 2034
(8 years from now) | |
| US9855211 | LNHC | Topical compositions and methods of using the same |
Feb, 2034
(8 years from now) | |
| US9737561 | LNHC | Topical gels and methods of using the same |
Aug, 2030
(4 years from now) | |
| US9289442 | LNHC | Topical compositions |
Jul, 2032
(6 years from now) | |
| US11285098 | LNHC | Topical compositions and methods of using the same |
Feb, 2034
(8 years from now) | |
| US10376538 | LNHC | Topical gels and methods of using the same |
Aug, 2030
(4 years from now) | |
| US9526738 | LNHC | Topical gels and methods of using the same |
Sep, 2031
(5 years from now) | |
| US10265334 | LNHC | Anhydrous compositions |
Jul, 2032
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 05, 2029 |
Drugs and Companies using BERDAZIMER SODIUM ingredient
NCE-1 date: 06 January, 2028
Market Authorisation Date: 05 January, 2024
Dosage: GEL
More Information on Dosage
ZELSUVMI family patents